Dolastatin 10(Synonyms: DLS 10 NSC 376128)

Dolastatin 10;(Synonyms: DLS 10; NSC 376128) 纯度: 98.63%

Dolastatin 10 (DLS 10) 是一种有效的抗有丝分裂肽,抑制微管蛋白聚合。

Dolastatin 10amp;;(Synonyms: DLS 10;  NSC 376128)

Dolastatin 10 Chemical Structure

CAS No. : 110417-88-4

规格 价格 是否有货 数量
1 mg ¥3000 In-stock
5 mg ¥8000 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

Dolastatin 10 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Toxins for Antibody-Drug Conjugate Research Library
  • Peptide Library

生物活性

Dolastatin 10 (DLS 10) is a potent antimitotic peptide that inhibits tubulin polymerization.

IC50 Target

Auristatin

;

体外研究
(In Vitro)

Dolastatin 10 is a unique pentapeptide that isolated from the sea hare Dolabella auricularia. These in vitro data are quite comparable to those of Dolastatin 10 and Auristatin PE, each of which has GI50 values of 10−5-10−6 μg/mL (10−2-10−3 nM) against a similar minipanel of human cell lines[2]. The antibody-drug conjugate (ADC) comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), a synthetic analog of the tubulin polymerization inhibitor Dolastatin 10[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

785.09

Formula

C42H68N6O6S

CAS 号

110417-88-4

中文名称

尾海兔素10

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

溶解性数据
In Vitro:;

DMSO : ≥ 100 mg/mL (127.37 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2737 mL 6.3687 mL 12.7374 mL
5 mM 0.2547 mL 1.2737 mL 2.5475 mL
10 mM 0.1274 mL 0.6369 mL 1.2737 mL

*

请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用

参考文献
  • [1]. Pitot HC, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999 Mar;5(3):525-31.

    [2]. Pettit GR, et al. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications ofdolastatin 10. J Nat Prod. 2011 May 27;74(5):962-8.

    [3]. Brentuximab vedotin. Drugs R D. 2011;11(1):85-95.

发表回复